Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,404.00
Bid: 12,424.00
Ask: 12,426.00
Change: 58.00 (0.47%)
Spread: 2.00 (0.016%)
Open: 12,334.00
High: 12,470.00
Low: 12,322.00
Prev. Close: 12,346.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) Pfizer Inc

22 May 2014 10:50

RNS Number : 8151H
Morgan Stanley Capital Services LLC
22 May 2014
 



 

 FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Morgan Stanley Capital Services LLC

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

PFIZER INC

(c) Name of the party to the offer with which exempt principal trader is connected:

 

ASTRAZENECA PLC

(d) Date dealing undertaken:

21 MAY 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

 Class of relevant security

 Purchases/sales

 Total number of securities

 Highest price per unit paid/received

 Lowest price per unit paid/received

 COMMON STOCK

 PURCHASES

 239,238

 29.6203 USD

 29.2700 USD

 COMMON STOCK

 SALES

 339,974

 29.6203 USD

 29.2400 USD

 

 

(b) Derivatives transactions (other than options)

 

 Class of relevant security

 Product description

e.g. CFD

 Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

 Number of reference securities

 Price per unit

 COMMON STOCK

 CFD

 LONG

 1,300

 29.3900 USD

 COMMON STOCK

 CFD

 LONG

 21,480

 29.4411 USD

 COMMON STOCK

 CFD

 LONG

 2,200

 29.4420 USD

 COMMON STOCK

 CFD

 LONG

 13,400

 29.4960 USD

 COMMON STOCK

 CFD

 LONG

 38,900

 29.5316 USD

 COMMON STOCK

 CFD

 LONG

 5

 29.5360 USD

 COMMON STOCK

 CFD

 LONG

 13,681

 29.5407 USD

 COMMON STOCK

 CFD

 LONG

 60,085

 29.5415 USD

 COMMON STOCK

 CFD

 LONG

 32,134

 29.5420 USD

 COMMON STOCK

 CFD

 LONG

 123

 29.5428 USD

 COMMON STOCK

 CFD

 LONG

 2

 29.5428 USD

 COMMON STOCK

 CFD

 LONG

 2

 29.5431 USD

 COMMON STOCK

 CFD

 LONG

 111

 29.5431 USD

 COMMON STOCK

 CFD

 LONG

 1

 29.5432 USD

 COMMON STOCK

 CFD

 LONG

 110

 29.5432 USD

 COMMON STOCK

 CFD

 LONG

 2,900

 29.5436 USD

 COMMON STOCK

 CFD

 LONG

 2

 29.5463 USD

 COMMON STOCK

 CFD

 LONG

 30

 29.5463 USD

 COMMON STOCK

 CFD

 LONG

 100

 29.5500 USD

 COMMON STOCK

 CFD

 LONG

 4,200

 29.5500 USD

 COMMON STOCK

 CFD

 LONG

 5,500

 29.5554 USD

 COMMON STOCK

 CFD

 LONG

 29,692

 29.5630 USD

 COMMON STOCK

 CFD

 LONG

 21,700

 29.5677 USD

 COMMON STOCK

 CFD

 LONG

 5

 29.5680 USD

 COMMON STOCK

 CFD

 LONG

 79,605

 29.5730 USD

 COMMON STOCK

 CFD

 LONG

 1,992

 29.5753 USD

 COMMON STOCK

 CFD

 LONG

 700

 29.5785 USD

 COMMON STOCK

 CFD

 LONG

 1,818

 29.5788 USD

 COMMON STOCK

 CFD

 LONG

 279

 29.5788 USD

 COMMON STOCK

 CFD

 SHORT

 1

 29.4800 USD

 COMMON STOCK

 CFD

 SHORT

 400

 29.5300 USD

 COMMON STOCK

 CFD

 SHORT

 9,600

 29.5458 USD

 COMMON STOCK

 CFD

 SHORT

 300

 29.5500 USD

 COMMON STOCK

 CFD

 SHORT

 2,200

 29.5600 USD

 COMMON STOCK

 CFD

 SHORT

 500

 29.5625 USD

 COMMON STOCK

 CFD

 SHORT

 125,000

 29.5700 USD

 COMMON STOCK

 CFD

 SHORT

 1,000

 29.5700 USD

 COMMON STOCK

 CFD

 SHORT

 45,500

 29.5747 USD

 COMMON STOCK

 CFD

 SHORT

 18,100

 29.5842 USD

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

 Class of relevant security

 Product description e.g. call option

 Writing, purchasing, selling, varying etc.

 Number of securities to which option relates

 Exercise price per unit

 Type e.g. American, European etc.

 Expiry date

 Option money paid/ received per unit

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 

(ii) Exercising

 

 Class of relevant security

 Product description e.g. call option

 Number of securities

 Exercise price per unit

 N/A

 N/A

 N/A

 N/A

 

(d) Other dealings (including subscribing for new securities)

 

 Class of relevant security

 Nature of dealing e.g. subscription, conversion

 Details

 Price per unit (if applicable)

 N/A

 N/A

 N/A

 N/A

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

Date of disclosure:

22 MAY 2014

Contact name:

Darren Wickert

Telephone number:

+44 (0)20 7425 6578

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERGCGDURSDBGSD
Date   Source Headline
29th Mar 20195:15 pmRNSResults of Placing
29th Mar 20197:00 amRNSProposed placing of new ordinary shares
29th Mar 20197:00 amRNSAZ and Daiichi Sankyo enter collaboration in novel
27th Mar 20197:00 amRNSForxiga approved in Japan for type-1 diabetes
25th Mar 20197:00 amRNSForxiga approved in Europe for type-1 diabetes
18th Mar 20197:00 amRNSUS FDA grants saracatinib ODD for IPF
14th Mar 201912:00 pmRNSNotice of AGM
12th Mar 201912:00 pmRNSDirector/PDMR Shareholding
6th Mar 20197:00 amRNSFiling of Form 20-F with SEC
5th Mar 201911:00 amRNSAnnual Financial Report
4th Mar 20194:04 pmRNSHolding(s) in Company
1st Mar 20193:00 pmRNSTotal Voting Rights
1st Mar 20191:45 pmRNSLynparza receives positive EU CHMP opinion
26th Feb 20197:00 amRNSLynparza significantly delayed disease progression
25th Feb 20197:00 amRNSBrilinta's PhIII THEMIS trial met primary endpoint
14th Feb 20197:00 amRNSAstraZeneca Full-Year and Q4 2018 Results
6th Feb 20197:00 amRNSUS FDA grants Fasenra Orphan Drug Designation
5th Feb 20197:05 amRNSUS FDA grants Breakthrough Therapy Designation
5th Feb 20197:00 amRNSEMA grants PRIME eligibility for MEDI8897
1st Feb 20193:00 pmRNSTotal Voting Rights
1st Feb 20191:17 pmRNSForxiga receives positive EU CHMP opinion
25th Jan 20192:00 pmRNSCompletion of divestment of US Synagis rights
7th Jan 20191:00 pmRNSAstraZeneca announces organisational changes
2nd Jan 20193:00 pmRNSTotal Voting Rights
20th Dec 20181:47 pmRNSBevespi Aerosphere approved in the EU for COPD
20th Dec 20187:05 amRNSLynparza meets primary endpoint in SOLO-3 trial
20th Dec 20187:00 amRNSPhase III ROCKIES and OLYMPUS roxadustat trials
19th Dec 20186:31 pmRNSFDA approves Lynparza as 1L maintenance therapy
18th Dec 20189:09 amRNSRoxadustat approved in China for the treatment of
14th Dec 20187:00 amRNSDirectorate Change
7th Dec 20187:00 amRNSUpdate on the Phase III EAGLE trial of Imfinzi
6th Dec 20187:00 amRNSDivestment of rights to Covis completed
4th Dec 20183:00 pmRNSDirector/PDMR Shareholding
3rd Dec 20184:00 pmRNSBlock listing Interim Review
3rd Dec 20184:00 pmRNSTotal Voting Rights
3rd Dec 20187:00 amRNSGrünenthal Agreement for Nexium, Vimovo Completed
26th Nov 20187:00 amRNSUS FDA grants Fasenra ODD for EGPA
16th Nov 20187:00 amRNSAstraZeneca provides update on Phase III MYSTIC
13th Nov 20187:00 amRNSAstraZeneca to divest US Synagis rights to Sobi
12th Nov 20187:05 amRNSUS FDA accepts regulatory submission for Lynparza
12th Nov 20187:00 amRNSFarxiga significantly reduced hospitalisation for
8th Nov 20187:00 amRNSAZN: Year-to-Date and Q3 2018 Results
6th Nov 20187:00 amRNSDivestment of rights to Covis Pharma
1st Nov 20183:00 pmRNSTotal Voting Rights
31st Oct 20189:45 amRNSAdditional financial information-Grünenthal deal
30th Oct 20187:00 amRNSGrünenthal Agreement for rights to Nexium, Vimovo
23rd Oct 20187:00 amRNSAstraZeneca Extends Innate Pharma Collaboration
22nd Oct 20187:00 amRNSLynparza shows 70% reduction in PFS ovarian cancer
19th Oct 20181:09 pmRNSCHMP positive opinion Bevespi Aerosphere
16th Oct 20187:00 amRNSFDA Orphan Drug for Lynparza in pancreatic cancer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.